Yohei Hisada1, Charlotte Thålin2, Staffan Lundström3, Håkan Wallén4, Nigel Mackman5. 1. Department of Medicine, Division of Hematology and Oncology, Thrombosis and Hemostasis Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Department of Clinical Sciences, Danderyd Hospital, Division of Internal Medicine, Karolinska Institutet, Stockholm, Sweden. 3. Palliative Care Services, Stockholms Sjukhem Foundation, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 4. Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine, Karolinska Institutet, Stockholm, Sweden. 5. Department of Medicine, Division of Hematology and Oncology, Thrombosis and Hemostasis Program, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: nigel_mackman@med.unc.edu.
Abstract
INTRODUCTION: Increased levels of circulating tissue factor (TF)-positive microvesicles (MVs) may increase the risk of thrombosis. Indeed, TF-positive MVs are detected in plasma of patients with various types of diseases. In this study, we measured levels of MV TF activity in non-cancer severely ill patients and cancer patients. METHODS: We used an in-house MV TF activity assay to measure MV TF activity. RESULTS: MV TF activity was significantly increased in a population of cancer patients but not in a population of non-cancer severely ill patients compared with healthy controls. However, in the population of severely ill patients, those with infection had significantly elevated levels of MV TF activity compared with controls. Interestingly, patients with adenocarcinoma had higher levels of MV TF activity compared with patients with non-adenocarcinoma tumors. Levels of MV TF activity were not associated with venous thromboembolism in cancer patients. MV TF activity was associated with reduced survival in cancer patients. CONCLUSION: Cancer patients as well as severely ill patients with infection have higher levels of MV TF activity compared with healthy controls. Patients with adenocarcinoma have higher levels of MV TF activity compared with patients with other types of cancer. An elevated level of MV TF activity was associated with reduced survival in cancer patients.
INTRODUCTION: Increased levels of circulating tissue factor (TF)-positive microvesicles (MVs) may increase the risk of thrombosis. Indeed, TF-positive MVs are detected in plasma of patients with various types of diseases. In this study, we measured levels of MV TF activity in non-cancer severely ill patients and cancerpatients. METHODS: We used an in-house MV TF activity assay to measure MV TF activity. RESULTS: MV TF activity was significantly increased in a population of cancerpatients but not in a population of non-cancer severely ill patients compared with healthy controls. However, in the population of severely ill patients, those with infection had significantly elevated levels of MV TF activity compared with controls. Interestingly, patients with adenocarcinoma had higher levels of MV TF activity compared with patients with non-adenocarcinoma tumors. Levels of MV TF activity were not associated with venous thromboembolism in cancerpatients. MV TF activity was associated with reduced survival in cancerpatients. CONCLUSION:Cancerpatients as well as severely ill patients with infection have higher levels of MV TF activity compared with healthy controls. Patients with adenocarcinoma have higher levels of MV TF activity compared with patients with other types of cancer. An elevated level of MV TF activity was associated with reduced survival in cancerpatients.
Authors: Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné Journal: Blood Date: 2015-07-07 Impact factor: 22.113
Authors: Joshua G Cohen; Emily Prendergast; Julia E Geddings; Ann E Walts; Hasmik Agadjanian; Yohei Hisada; Beth Y Karlan; Nigel Mackman; Christine S Walsh Journal: Gynecol Oncol Date: 2017-05-10 Impact factor: 5.482
Authors: R Nieuwland; R J Berckmans; S McGregor; A N Böing; F P Romijn; R G Westendorp; C E Hack; A Sturk Journal: Blood Date: 2000-02-01 Impact factor: 22.113
Authors: Johannes J A Auwerda; Yuana Yuana; Susanne Osanto; Moniek P M de Maat; Pieter Sonneveld; Rogier M Bertina; Frank W G Leebeek Journal: Thromb Haemost Date: 2010-11-05 Impact factor: 5.249
Authors: David A Manly; Jianguo Wang; Sam L Glover; Raj Kasthuri; Howard A Liebman; Nigel S Key; Nigel Mackman Journal: Thromb Res Date: 2009-10-24 Impact factor: 3.944
Authors: Raymond C Rancourt; Jacqueline S Rioux; Livia A Veress; Rhonda B Garlick; Claire R Croutch; Eric Peters; William Sosna; Carl W White Journal: Drug Chem Toxicol Date: 2018-11-14 Impact factor: 3.356